$GOVX
GeoVax Labs, Inc.

2024 Q1 Form 10-K Financial Statement

#000143774924006086 Filed on February 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.457M $1.460M $6.022M
YoY Change 0.41% -10.05% 20.77%
% of Gross Profit
Research & Development $4.426M $6.234M $20.72M
YoY Change 56.99% 65.59% 127.11%
% of Gross Profit
Depreciation & Amortization $19.58K $22.21K $74.17K
YoY Change 13.03% 57.85% 31.78%
% of Gross Profit
Operating Expenses $5.883M $7.694M $26.74M
YoY Change 37.76% 42.81% 89.53%
Operating Profit -$5.883M -$26.74M
YoY Change 37.76% 90.63%
Interest Expense $33.00K $101.3K $776.2K
YoY Change -85.82% 2646.34%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.850M -$7.592M -$25.97M
YoY Change 44.88% 41.02% 85.2%
Income Tax
% Of Pretax Income
Net Earnings -$5.850M -$7.592M -$25.97M
YoY Change 44.88% 41.02% 85.2%
Net Earnings / Revenue
Basic Earnings Per Share -$2.47 -$14.29
Diluted Earnings Per Share -$2.47 -$3.83 -$14.29
COMMON SHARES
Basic Shares Outstanding 2.172M 26.70M 1.817M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $768.9K $6.453M $6.453M
YoY Change -96.78% -76.63% -76.63%
Cash & Equivalents $768.9K $6.453M $6.453M
Short-Term Investments
Other Short-Term Assets $2.094M $1.433M $1.433M
YoY Change -2.12% 8.08% 8.08%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $2.862M $7.886M $7.886M
YoY Change -88.99% -72.75% -72.75%
LONG-TERM ASSETS
Property, Plant & Equipment $190.1K $209.7K $209.7K
YoY Change -12.63% -10.74% -10.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $305.7K $1.188M $1.188M
YoY Change -74.48% -45.37% -45.37%
Total Long-Term Assets $495.8K $1.397M $1.397M
YoY Change -64.97% -41.99% -41.99%
TOTAL ASSETS
Total Short-Term Assets $2.862M $7.886M $7.886M
Total Long-Term Assets $495.8K $1.397M $1.397M
Total Assets $3.358M $9.283M $9.283M
YoY Change -87.75% -70.39% -70.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.884M $2.803M $2.803M
YoY Change 46.26% 60.38% 60.38%
Accrued Expenses $1.420M $716.9K $716.9K
YoY Change -56.32% -76.1% -76.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.304M $3.520M $3.520M
YoY Change -27.21% -25.86% -25.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.304M $3.520M $3.520M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.304M $3.520M $3.520M
YoY Change -27.21% -25.86% -25.86%
SHAREHOLDERS EQUITY
Retained Earnings -$110.2M -$104.4M
YoY Change 33.7% 33.12%
Common Stock $110.3M $110.1M
YoY Change 4.72% 4.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $54.28K $5.763M $5.763M
YoY Change
Total Liabilities & Shareholders Equity $3.358M $9.283M $9.283M
YoY Change -87.75% -70.39% -70.39%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$5.850M -$7.592M -$25.97M
YoY Change 44.88% 41.02% 85.2%
Depreciation, Depletion And Amortization $19.58K $22.21K $74.17K
YoY Change 13.03% 57.85% 31.78%
Cash From Operating Activities -$5.684M -$10.28M -$25.17M
YoY Change 51.05% 45.49% 32.28%
INVESTING ACTIVITIES
Capital Expenditures $18.95K $48.95K
YoY Change -63.54%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$18.95K -$48.95K
YoY Change -63.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.062M $4.062M
YoY Change -88.51%
NET CHANGE
Cash From Operating Activities -$5.684M -10.28M -$25.17M
Cash From Investing Activities -18.95K -$48.95K
Cash From Financing Activities 4.062M $4.062M
Net Change In Cash -$5.684M -6.234M -$21.16M
YoY Change 51.05% -11.75% -230.71%
FREE CASH FLOW
Cash From Operating Activities -$5.684M -$10.28M -$25.17M
Capital Expenditures $18.95K $48.95K
Free Cash Flow -$10.30M -$25.22M
YoY Change 45.76% 31.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-14.29
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1817282
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1131546
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0000832489
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
14363801 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2172272
CY2023 dei Auditor Firm
AuditorFirmId
344
CY2023 dei Auditor Name
AuditorName
WIPFLI LLP
CY2023 dei Auditor Location
AuditorLocation
Atlanta, Georgia
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6452589 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27612732 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1433153 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1325998 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7885742 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
28938730 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
209689 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
234912 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1187788 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2174286 usd
CY2023Q4 us-gaap Assets
Assets
9283219 usd
CY2022Q4 us-gaap Assets
Assets
31347928 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2802950 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1747682 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
716931 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3000212 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3519881 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4747894 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1977152
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1977152
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1755664
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1755664
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1977 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1756 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
110125146 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
104995301 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104363785 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78397023 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5763338 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
26600034 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9283219 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31347928 usd
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
81526 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20720766 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9123479 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6022173 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4986611 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
14110090 usd
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
776177 usd
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
7439 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-25966762 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14021125 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.39
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4361704 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27727194 usd
CY2022 govx Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
7626134 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
773377 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14021125 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
26600034 usd
CY2023 govx Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
4062442 usd
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
212500 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
855124 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-25966762 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5763338 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-25966762 usd
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
74169 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
56284 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1074957 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
902074 usd
CY2023 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-0 usd
CY2022 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-49006 usd
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
114488 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1165705 usd
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-986498 usd
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2163276 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1228013 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2687466 usd
CY2023 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
793123 usd
CY2022 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-5009083 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25173639 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19030208 usd
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48946 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
134258 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48946 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-134258 usd
CY2023 govx Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 usd
CY2022 govx Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
27727194 usd
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4062442 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7626134 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4062442 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35353328 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21160143 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16188862 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27612732 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11423870 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6452589 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27612732 usd
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>1.</b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Nature of Business </b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">GeoVax Labs, Inc., headquartered in the Atlanta, Georgia metropolitan area, is a clinical-stage biotechnology company incorporated under the laws of the State of Delaware. GeoVax Labs, Inc. and its wholly owned subsidiary, GeoVax, Inc., a Georgia corporation, are collectively referred to herein as “GeoVax” or the “Company”.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company is focused on developing immunotherapies and vaccines against cancers and infectious diseases using novel vector vaccine platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation Covid-19 vaccine and a gene-directed therapy for advanced head and neck cancer. Additional preclinical research and development programs include preventive vaccines against Mpox (monkeypox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa Fever) Zika virus, and malaria, as well as immunotherapies for solid tumors.</p>
CY2023 us-gaap Use Of Estimates
UseOfEstimates
The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1731391
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1029529
CY2023Q4 govx Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1282746 usd
CY2022Q4 govx Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1171077 usd
CY2023 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Period-to-Period Comparisons</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results for future periods.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
110695 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
107876 usd
CY2023Q4 us-gaap Prepaid Rent
PrepaidRent
13045 usd
CY2022Q4 us-gaap Prepaid Rent
PrepaidRent
13045 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
26667 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
34000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1433153 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1325998 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
890363 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
841417 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
680674 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
606505 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
209689 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
234912 usd
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
74169 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
56284 usd
CY2023Q4 govx Prepaid Clinical Trial Expenses Noncurrent
PrepaidClinicalTrialExpensesNoncurrent
1106778 usd
CY2022Q4 govx Prepaid Clinical Trial Expenses Noncurrent
PrepaidClinicalTrialExpensesNoncurrent
2083276 usd
CY2023Q4 govx Prepaid Technology License Fees
PrepaidTechnologyLicenseFees
70000 usd
CY2022Q4 govx Prepaid Technology License Fees
PrepaidTechnologyLicenseFees
80000 usd
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
11010 usd
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
11010 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1187788 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2174286 usd
CY2023Q4 govx Accrued License Fees Current
AccruedLicenseFeesCurrent
0 usd
CY2022Q4 govx Accrued License Fees Current
AccruedLicenseFeesCurrent
2000000 usd
CY2023Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
114337 usd
CY2022Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
550810 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
602594 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
449402 usd
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
716931 usd
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
3000212 usd
CY2023 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
24021
CY2022 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
9567
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2438423
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.10 pure
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
137276
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.35
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
-0 usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2667
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
22.82
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
134609
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.41
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
97184
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
32.35
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2103813
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0354 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.60 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.98
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
554592 usd
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2023Q4 govx Prepaid Expense Value Of Stock Issued For Services During Period
PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod
16667 usd
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1074957 usd
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
902074 usd
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
95658 usd
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
53643 usd
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25527210 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19764569 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3870460 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2202603 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
552886 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
330553 usd
CY2023Q4 govx Deferred Tax Assets Accrued Salaries
DeferredTaxAssetsAccruedSalaries
29728 usd
CY2022Q4 govx Deferred Tax Assets Accrued Salaries
DeferredTaxAssetsAccruedSalaries
663211 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
29980284 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22960936 usd
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
45122 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
51466 usd
CY2023Q4 govx Deferred Tax Assets Before Valuation Allowance Net
DeferredTaxAssetsBeforeValuationAllowanceNet
29935162 usd
CY2022Q4 govx Deferred Tax Assets Before Valuation Allowance Net
DeferredTaxAssetsBeforeValuationAllowanceNet
22909470 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
29935162 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22909470 usd
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
-0 usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
-0 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.039 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.039 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0 pure
CY2023 govx Effective Income Tax Rate Reconciliation Nol Carryforward Expiration Percent
EffectiveIncomeTaxRateReconciliationNOLCarryforwardExpirationPercent
-0.043 pure
CY2022 govx Effective Income Tax Rate Reconciliation Nol Carryforward Expiration Percent
EffectiveIncomeTaxRateReconciliationNOLCarryforwardExpirationPercent
-0.156 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.064 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.046 pure
CY2023 govx Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance And Other Adjustments Percent
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowanceAndOtherAdjustmentsPercent
-0.27 pure
CY2022 govx Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance And Other Adjustments Percent
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowanceAndOtherAdjustmentsPercent
-0.139 pure
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000

Files In Submission

Name View Source Status
govx-20231231_cal.xml Edgar Link unprocessable
0001437749-24-006086-index-headers.html Edgar Link pending
0001437749-24-006086-index.html Edgar Link pending
0001437749-24-006086.txt Edgar Link pending
0001437749-24-006086-xbrl.zip Edgar Link pending
ex_629083.htm Edgar Link pending
ex_629084.htm Edgar Link pending
ex_629085.htm Edgar Link pending
ex_629086.htm Edgar Link pending
ex_629087.htm Edgar Link pending
ex_631302.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
govx-20231231.xsd Edgar Link pending
govx20231231_10k.htm Edgar Link pending
govx20231231_10kimg001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
govx-20231231_def.xml Edgar Link unprocessable
govx-20231231_lab.xml Edgar Link unprocessable
govx-20231231_pre.xml Edgar Link unprocessable
govx20231231_10k_htm.xml Edgar Link completed
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wipflilogo.jpg Edgar Link pending